WO2019196714A1 - Dérivé d'acrylamide n-substitué en tant qu'inhibiteur de dhodh, sa préparation et son utilisation - Google Patents

Dérivé d'acrylamide n-substitué en tant qu'inhibiteur de dhodh, sa préparation et son utilisation Download PDF

Info

Publication number
WO2019196714A1
WO2019196714A1 PCT/CN2019/081066 CN2019081066W WO2019196714A1 WO 2019196714 A1 WO2019196714 A1 WO 2019196714A1 CN 2019081066 W CN2019081066 W CN 2019081066W WO 2019196714 A1 WO2019196714 A1 WO 2019196714A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
substituted
unsubstituted
reacted
Prior art date
Application number
PCT/CN2019/081066
Other languages
English (en)
Chinese (zh)
Inventor
徐晓勇
李洪林
李忠
李诗良
曾凡勋
王蕊
章乐天
朱丽丽
齐甜甜
Original Assignee
华东理工大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华东理工大学 filed Critical 华东理工大学
Publication of WO2019196714A1 publication Critical patent/WO2019196714A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the field of medicinal chemistry and pharmacotherapy, and in particular to N-substituted acrylamide derivatives as DHODH inhibitors, and their preparation and use.
  • Dihydroorotate dehydrogenase is an iron-containing flavin-dependent mitochondrial enzyme that is the intracellular rate-limiting enzyme in the synthesis of nucleoside pyrimidines and catalyzes the fourth step in the biosynthesis pathway from cephalin. . Inhibition of DHODH can block the synthesis of neonatal pyrimidines, resulting in DNA and RNA synthesis barriers. There are two ways to synthesize pyrimidine in most organisms: the salvage pathway and de novo synthesis from small molecules.
  • the demand for pyrimidine in an organism depends on the cell type and the stage of differentiation in which the cells in the resting and differentiated phases acquire only a small fraction of the pyrimidines through the de novo synthesis pathway, and rely mainly on the salvage pathway.
  • rapidly differentiated human cells such as activated T-lymphocytes, B-lymphocytes, and tumor cells need to rely on pyrimidine de novo synthesis to satisfy them.
  • Leflunomide marketed in 1998, is a new type of isoxazole immunomodulator, which is mainly used for the treatment of autoimmune diseases such as rheumatoid arthritis and lupus erythematosus and acute and chronic anti-organ transplantation. Rejection and prevention of xenogeneic rejection. It was later discovered that leflunomide is a prodrug that is rapidly converted to the active metabolite A771726 (MI) via the cytoplasm and microsomes of the liver and intestinal wall after oral administration. MI is a good human dihydroorotate dehydrogenase inhibitor that blocks the de novo biosynthesis of pyrimidines and thus the synthesis of DNA and RNA. Studies have shown that MI can be used to prevent, treat or inhibit a variety of autoimmune diseases, acute and chronic rejection of organ transplantation and xenogeneic rejection, skin diseases such as psoriasis, and diversity hardening.
  • autoimmune diseases such as rheumatoid arthritis and l
  • Buquina originally developed as an anticancer drug, is one of the most potent DHODH inhibitors, but clinical phase II experiments have demonstrated its anti-tumor effect, and the compound continues to be developed as an immunosuppressive agent. 4SC-101 has been shown to have a good inhibitory effect on lupus erythematosus and enteritis, and is in the clinical development stage.
  • a first aspect of the invention provides a compound of formula I, or a stereoisomer thereof, a cis-trans isomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt or solvate thereof, or Crystal form:
  • A is an unsubstituted or substituted C 3-7 cycloalkyl group, an unsubstituted or substituted C 5-7 cycloalkenyl group, an unsubstituted or substituted C 6 -C 10 aryl group, or an unsubstituted or substituted 5-10 a heterocyclic group; said substituted means substituted with a group selected from the group consisting of halogen, cyano, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl , C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-NH-CO-, -O-(CH 2 )mO-, -(CH 2 ) n-; wherein m or n
  • B is an unsubstituted or substituted C 3-7 cycloalkyl group, a C 5-7 cycloalkenyl group, a C 6 -C 10 aryl group, a 5-10 membered heterocyclic group;
  • the substituted group means selected from the group consisting of Substituted by: a halogen, a cyano group (-CN), a nitro group, a carboxyl group (-COOH), an amide group (-CONH 2 ), a sulfonic acid group, a sulfonamide, a C 1-6 sulfonate group, a hydroxyl group, C 1-6 alkylcarbonyl, C 1-6 haloalkylcarbonyl, C 1-6 aldehyde, C 1-6 ester, C 1-6 hydrazide, fluorenyl, C 1-6 alkyl, C 1-6 Haloalkyl, C 3-7 cycloalkyl, C 2-6 alkenyl, C
  • R 1 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl;
  • R 2 is selected from the group consisting of hydrogen, halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl.
  • the compound is selected from the group consisting of the compounds of formula II:
  • a and R 2 are defined as before;
  • X represents a nitrogen atom or a group CY, wherein Y is selected from the group consisting of a carboxyl group, an amide group, a sulfonic acid group, a sulfonamide group, a C 1-6 sulfonate group, a hydroxyl group, a C 1-6 alkylcarbonyl group, and C 1- 6 haloalkylcarbonyl, C 1-6 aldehyde, C 1-6 ester, C 1-6 hydrazide, cyano, nitro, fluorenyl;
  • R 3 , R 4 , R 5 are each independently selected from the group consisting of hydrogen, halogen, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, C 2 -6 alkenyl, C 1-6 alkoxy, hydroxy, C 1-6 haloalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-NH- CO-, -O-CH 2 -O-, -(CH 2 )n-; wherein n is an integer of 2 to 4.
  • the Y is selected from the group consisting of a carboxyl group, an amide group, and a cyano group.
  • A is an unsubstituted or substituted phenyl group, an unsubstituted or substituted pyridyl group, an unsubstituted or substituted indenyl group, an unsubstituted or substituted naphthyl group, an unsubstituted or substituted thienyl group, Unsubstituted or substituted benzothienyl, unsubstituted or substituted furyl, unsubstituted or substituted benzofuranyl, unsubstituted or substituted quinoline or unsubstituted or substituted isoquinolyl.
  • A is selected from the group consisting of:
  • R 2 is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, trifluoromethyl, methyl, ethyl, propyl, cyclopropyl.
  • R 3 , R 4 , R 5 are each independently selected from the group consisting of hydrogen, halogen, cyano, nitro, C 1-4 alkyl, C 1-4 halogenated alkane, C 3-7 cycloalkane.
  • Base C 1-4 alkoxy group, hydroxyl group.
  • each of R 3 , R 4 and R 5 is independently hydrogen, fluorine, chlorine, cyano, trifluoromethyl, methyl, ethyl, methoxy, cyclopropyl or hydroxy.
  • the compound is selected from the group consisting of compounds of formula III:
  • R 6 , R 7 , R 8 , R 9 and R 10 are each independently selected from the group consisting of hydrogen, halogen, cyano, nitro, C 1-6 alkyl, C 1-6 halogenated alkane, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 5-7 cycloalkenyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 6 -C 10 aryl, C 6 - C 10 aryloxy, 5- or 6-membered heterocyclic group, hydroxy group, C 6 -C 10 aryl-NH-CO-;
  • B is selected from unsubstituted or substituted phenyl, unsubstituted or substituted 5- or 6-membered heterocyclic groups, or unsubstituted or substituted C 5-7 cycloalkenyl.
  • the 5- or 6-membered heterocyclic group is selected from the group consisting of pyridyl, thienyl, and furyl.
  • B is selected from the group consisting of:
  • a second aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of the first aspect, or a stereoisomer thereof, a cis-trans isomer thereof, a tautomer thereof, a prodrug thereof or a pharmaceutically acceptable salt or solvate or crystalline form thereof; and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition is an injection, a capsule (such as a hard and soft gelatin capsule), a tablet, a coated tablet, a pill, a powder, a granule, a sugar-coated tablet, a solution, a syrup Agents, emulsions, suspensions, aerosols, suppositories, infusions, ointments, creams and elixirs.
  • a capsule such as a hard and soft gelatin capsule
  • a tablet such as a hard and soft gelatin capsule
  • a tablet such as a hard and soft gelatin capsule
  • a coated tablet such as a coated tablet
  • a pill such as a coated tablet
  • a pill such as a coated tablet
  • a pill such as a coated tablet
  • a pill such as a coated tablet
  • a pill such as a coated tablet
  • a pill such as a coated tablet
  • a pill such as a coated tablet
  • a pill such as a coated tablet
  • a pill
  • a third aspect of the invention provides the compound of the first aspect, or a stereoisomer thereof, a cis-trans isomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt or solvate thereof Or a use of the pharmaceutical composition of the second aspect, for the preparation of a dihydroorotate dehydrogenase inhibitor; for the preparation of a pyrimidine biosynthetic enzyme inhibitor; and/or for the preparation of a prophylactic or therapeutic Inhibition of hydrogen orotate dehydrogenase and/or inhibition of pyrimidine biosynthetic enzymes to improve pathological conditions or diseases.
  • the pathological condition or disease is selected from the group consisting of cancer, rheumatoid arthritis, colitis, lupus erythematosus, glomerular disease, anti-organ transplant rejection, melanoma, silver shavings Disease, arthritis, fibrosis, rhinitis, psoriasis, multiple sclerosis, uveitis, asthma, leukemia and malaria.
  • a fourth aspect of the invention provides the compound of the first aspect, or a stereoisomer thereof, a cis-trans isomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt or solvate thereof Type preparation method,
  • the method is method 1, comprising the steps of:
  • method 4 including the steps of:
  • the compound 12 is subjected to a hydrolysis reaction to form a compound 13;
  • the compound 17 is subjected to a hydrolysis reaction to form a compound 18;
  • the compound 24 is subjected to a hydrolysis reaction to form a compound 25;
  • the present invention provides a method of treatment or prevention comprising administering to a subject in need thereof the compound of the present invention, or a stereoisomer thereof, a cis-trans isomer thereof, a tautomer thereof, a prodrug thereof or A pharmaceutically acceptable salt or solvate or crystalline form thereof or a pharmaceutical composition of the invention.
  • the compound is a compound of Formula I, Formula II, or Formula III.
  • C 1-6 alkyl refers to a straight or branched alkyl group having from 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, A sec-butyl group, a tert-butyl group, or the like.
  • C 2-6 alkenyl refers to a straight or branched alkenyl group having 2 to 6 carbon atoms, such as ethenyl, allyl, propenyl, isopropenyl, 1-butenyl, 2- Butenyl, or a similar group.
  • C 2-6 alkynyl refers to a straight or branched alkynyl group having 2 to 6 carbon atoms, such as an ethynyl group, a propynyl group, or the like.
  • C 3-7 cycloalkyl refers to a cyclic alkyl group having from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or the like.
  • C 5-7 cycloalkenyl refers to a cyclic alkenyl group having from 5 to 7 carbon atoms having one or more double bonds, such as cyclopentenyl, cyclohexenyl, cycloheptenyl, 1 , 3-cyclohexadienyl, 1,4-cyclohexadienyl, or the like.
  • C1-6 alkoxy refers to a straight or branched alkoxy group having from 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, Butoxy, isobutoxy, sec-butoxy, tert-butoxy, or the like.
  • halogen means fluoro, chloro, bromo, or iodo.
  • C 1-6 haloalkane refers to a straight or branched chain alkane having from 1 to 6 carbon atoms which is substituted by the same or different one or more of the above halogen atoms, such as trifluoromethyl, pentafluoroethyl, Heptafluoroisopropyl, or a similar group.
  • aryl refers to a monocyclic, bicyclic or tricyclic aromatic group containing from 6 to 14 carbon atoms, including phenyl, naphthyl, phenanthryl, anthracenyl, fluorenyl, fluorenyl, tetrahydronaphthyl, Indane or the like.
  • an aryl group can be optionally substituted with one or more substituents as described herein.
  • aryloxy refers to aryl-O-, for example phenoxy (
  • the curve mark is the substitution position, the same as above and below.
  • heterocyclyl refers to a single or fused ring structure, which may be aromatic and non-aromatic in nature, and which preferably contains from 3 to 20 ring atoms, more preferably from 5 to 14 or 5 to 10
  • One or more ring atoms, at least one and preferably up to 4 are heteroatoms selected from nitrogen, oxygen or sulfur.
  • examples of the heterocyclic group include furyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, triazolyl, thiazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridine , pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzoxazolyl, benzothienyl, benzofuran , morpholinyl, oxazolyl, dibenzothiophenyl, 1,2-methylenedioxyphenyl, fluorenyl, oxazolyl, benzimidazolyl, benzo[d][1,2 , 3] thiadiazolyl, imidazo[1,2-a]pyridyl, porphyrinyl,
  • 5- or 6-membered heterocyclyl refers to a five- or six-membered ring containing one or more heteroatoms selected from nitrogen, oxygen or sulfur, such as pyridinyl, thiazolyl, thienyl, furanyl, pyrrolyl , pyrazolyl, pyrimidinyl, tetrahydrofuranyl, oxazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, or 1,3,4-oxadiazolyl, and the like.
  • C1-6 aldehyde group refers to -C1-5 alkyl-CHO.
  • the groups described in the present invention can be 0 to more (usually 0, 1, 2 or 3, whether or not specifically stated as “unsubstituted or optionally substituted” or not specifically stated as “unsubstituted or optionally substituted”. Substituted by a substituent selected from the group consisting of halogen, cyano, nitro, amino, carboxy, decyl, hydroxy, hydroxymethyl, C 1-4 aldehyde, C 1-6 alkyl, C 1-6 Haloalkyl (such as trifluoromethyl), halogen-substituted alkoxy (such as trifluoromethoxy), C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 5- 7 cycloalkenyl, C 1-6 alkoxy (such as methoxy), C 1-6 thioalkyl (such as pentafluorothiomethyl), C 1-6 thioalkoxy (such as pentafluorosulfur Methoxy),
  • the compounds of the present invention can be prepared by the following methods:
  • the starting aldehyde-based compound used can be purchased directly from the reagent company or by the following method:
  • the compound of the present invention can be synthesized by a method comprising the following steps:
  • the starting aldehyde-based compound can be directly purchased from a reagent company or synthesized by the following method.
  • the substituted aromatic acid (10 mmol) was weighed and dissolved in 25 mL of anhydrous THF, and argon gas was added thereto, and LiAlH 4 (20 mmol) was slowly added thereto in portions under ice-cooling. After reacting for 10 minutes in an ice bath, the mixture was reacted at room temperature for 4 hours. After the reaction was completed, the mixture was cooled in an ice bath, and 0.76 g of ice water, 0.76 g of a 15% aqueous NaOH solution, and 2.28 g of water were slowly added thereto in this order.
  • the substituted benzyl alcohol obtained in the previous step was dissolved in 100 mL of DCM, 70 mmol of MnO 2 was added under stirring, and reacted at room temperature for 4 h, filtered, and the filtrate was concentrated by spin-drying, and purified by column to obtain substituted aryl formaldehyde, the yield was 85-95%.
  • the substituted arylmethyl compound (5 mmol) was dissolved in 10 mL of CCl 4 , 10 mmol of NBS, 0.1 mmol of BPO was added, and the mixture was refluxed for 5 h, cooled to room temperature, filtered, and the filter cake was washed with an appropriate amount of petroleum ether and concentrated to dryness.
  • the obtained concentrate was dissolved in 10 mL of dioxane, added with 10 mL of water, 20 mmol of CaCO 3 , refluxed for 10 h, filtered, and extracted with ethyl acetate. The organic phase was combined, dried over anhydrous sodium sulfate The yield is about 80%.
  • the substituted benzyl alcohol (4 mmol) obtained in the previous step was dissolved in 40 mL of DCM, 28 mmol of MnO 2 was added under stirring, and reacted at room temperature for 4 h, filtered, and the filtrate was concentrated by spin-drying, and purified by column to obtain substituted aryl formaldehyde.
  • the yield was about 90. %.
  • the substituted aldehyde compound (5 mmol) was dispersed into 15 mL of DCM, and 9 mmol of ethoxyformylethylenetriphenylphosphine was added. The reaction was carried out for 12 h at room temperature, a part of the solvent was removed, and the column was purified to obtain 2-methyl-3-substituted acrylic acid.
  • the ethyl ester intermediate has a yield of about 95%.
  • the 2-methyl 3-substituted ethyl acrylate (4 mmol) obtained in the previous step was dissolved in 12 mL of THF and 12 mL of MeOH, and 16 mL of 2M aqueous NaOH solution was added.
  • the reaction was carried out at 40 ° C for 5 h. It was acidified with 1 M HCl, precipitated as a white solid, suction filtered, washed with an appropriate amount of water, and dried to give 2-methyl 3-substituted acrylic acid in a yield of about 95%.
  • the amino compound (1.2 mmol) was dissolved in 2 mL of DCM, 1.5 mmol of TEA and 0.1 mmol of DMAP were added and cooled in an ice bath.
  • the obtained acid chloride was dissolved in 1 mL of DCM, added dropwise to the reaction liquid, and reacted at room temperature until the end of the reaction. Acidified with 1 M HCl, solid precipitated, suction filtered, and recrystallized from ethanol to give the final product. The yield is about 70%.
  • the compound of the present invention can be synthesized by a method comprising the following steps:
  • the preparation of the starting material 2-methyl 3-substituted acrylic acid is similar to the preferred examples described above. Add 1 mmol of 2-methyl 3-substituted acrylic acid, 1.1 mmol of TsCl, 5 mL of DCE, 0.1 mmol of DMAP, 1.5 mmol of TEA, and react at 35 ° C for 1 h, add 1 mmol of amino compound, and react at 60 ° C for 10 h. Acidified with 1 M HCl, suction filtered to give a solid, washed with water, dried, and purified by column to give the desired product.
  • the compound of the present invention can be synthesized by a method comprising the following steps:
  • the compound of the present invention can be synthesized by a method comprising the following steps:
  • the compound of the present invention can be synthesized by a method comprising the following steps:
  • the compound of the present invention can be synthesized by a method comprising the following steps:
  • the compound of the present invention can be synthesized by a method comprising the following steps:
  • the compound of the present invention is a compound represented by the formula I or II or III or a stereoisomer thereof, a cis-trans isomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt or solvate thereof. Or crystal form.
  • Examples of the pharmaceutically acceptable salts of the present invention include, but are not limited to, inorganic and organic acid salts such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, and the like, formic acid, acetic acid, propionic acid, oxalic acid. , malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzene methanesulfonic acid, benzenesulfonic acid and other organic acids; and aspartic acid Acidic amino acids such as glutamic acid.
  • Another preferred class of salts are the salts of the compounds of the invention with bases, such as the alkali metal salts, especially the sodium and potassium salts.
  • the compound of the present invention has excellent DHODH inhibitory activity and can be used for the preparation of a medicament for treating or preventing DHODH-mediated diseases.
  • compositions of the present invention comprise a therapeutically effective amount of a compound of the invention together with a pharmaceutically acceptable carrier or excipient.
  • each active ingredient in the pharmaceutical compositions of the present invention can be determined by those skilled in the art, although the dosage of the drug required by each individual is different.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof is orally administered to a mammal daily, in an amount of from 0.0025 to 50 mg/kg body weight, preferably from about 0.01 to 10 mg per kg orally.
  • a unit oral dose can include from about 0.01 to 50 mg, preferably from about 0.1 to 10 mg, of a compound of the invention.
  • the unit dose may be administered one or more times per day in one or more tablets, each tablet containing from about 0.1 to 50 mg, more preferably from about 0.25 to 10 mg of the compound of the invention or a solvate thereof.
  • the pharmaceutical composition of the present invention can be formulated into a form suitable for various administration routes including, but not limited to, being formulated into parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, A form of nasal or topical administration for the treatment of tumors and other diseases.
  • the amount administered is an amount effective to ameliorate or eliminate one or more conditions.
  • an effective amount is an amount sufficient to ameliorate or in some way alleviate the symptoms associated with the disease.
  • Such doses can be administered as a single dose or can be administered according to an effective therapeutic regimen.
  • the amount administered may cure the disease, but administration is usually to improve the symptoms of the disease. Repeated administration is generally required to achieve the desired improvement in symptoms.
  • the dosage of the drug will be determined by the age, health and weight of the patient, the type of concurrent treatment, the frequency of treatment, and the desired therapeutic effect.
  • the pharmaceutical preparation of the present invention can be administered to any mammal as long as they can obtain the therapeutic effect of the compound of the present invention.
  • the most important of these mammals is humans.
  • the medicament of the present invention or a pharmaceutical composition thereof can be used for treating or preventing DHODH-mediated diseases including cancer, rheumatoid arthritis, colitis, lupus erythematosus, glomerular disease, anti-organ transplant rejection, melanoma , psoriasis, arthritis, fibrosis, rhinitis, psoriasis, multiple sclerosis, uveitis, asthma, leukemia, malaria, etc.
  • DHODH-mediated diseases including cancer, rheumatoid arthritis, colitis, lupus erythematosus, glomerular disease, anti-organ transplant rejection, melanoma , psoriasis, arthritis, fibrosis, rhinitis, psoriasis, multiple sclerosis, uveitis, asthma, leukemia, malaria, etc.
  • cancers include, but are not limited to, breast cancer, prostate cancer, head and neck squamous cell carcinoma
  • “Pharmaceutically acceptable carrier” means: one or more compatible solid or liquid fillers or gel materials which are suitable for human use and which must be of sufficient purity and of sufficiently low toxicity.
  • “compatibility” it is meant herein that the components of the composition are capable of blending with the compounds of the invention and with each other without significantly reducing the potency of the compound.
  • Pharmaceutically acceptable carriers include: fillers, bulking agents, disintegrating agents, binding agents, glidants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings or flavoring agents, A buffer substance or the like, and a solvent, a solubilizing agent or a reagent for obtaining a storage effect, a salt for changing the osmotic pressure, a coating reagent or an antioxidant, and the like.
  • examples of pharmaceutically acceptable carriers include cellulose and derivatives thereof (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as Stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as Tween) ), a wetting agent (such as sodium lauryl sulfate), pyrogen-free water, and the like.
  • cellulose and derivatives thereof such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
  • gelatin such as talc
  • solid lubricants such as Stearic acid, magnesium stearate
  • calcium sulfate such as soybean oil, sesame oil, peanut oil, olive
  • Solid dosage forms for oral administration include capsules (such as hard or soft gelatin capsules), tablets, pills, powders, and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with: (a) a filler or solubilizer, for example, starch , lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example , glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) slow solvent, such as paraffin; (f) absorption acceleration Agents, for example, quaternary ammonium compounds;
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other materials known in the art. They may contain opacifying agents and the release of the active compound or compound in such compositions may be released in a portion of the digestive tract in a delayed manner. Examples of embedding components that can be employed are polymeric and waxy materials. If necessary, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs.
  • the liquid dosage form may contain inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or a mixture of these substances.
  • inert diluents conventionally employed in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, especially cottonseed oil, peanut oil
  • compositions may contain adjuvants such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, and flavoring agents.
  • adjuvants such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, and flavoring agents.
  • the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, etc. .
  • compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and nonaqueous vehicles, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
  • Dosage forms for the compounds of the invention for topical administration include ointments, powders, patches, propellants and inhalants.
  • the active ingredient is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or, if necessary, propellants.
  • the compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds, for example, in combination with existing drugs for the treatment of the aforementioned diseases. In the latter case, an increase in efficacy can be observed.
  • Anthranilic acid (1.2 mmol) was dissolved in 2 mL of DCM, 1.5 mmol of TEA and 0.1 mmol of DMAP were added and cooled in an ice bath.
  • the obtained acid chloride was dissolved in 1 mL of DCM, added dropwise to the reaction liquid, and reacted at room temperature until the end of the reaction. Acidified with 1 M HCl, solid precipitated, suction filtered, and recrystallized from ethanol to give the final product. The yield was 70%.
  • the preparation method was similar to that of Example 1, except that 4-trifluoromethylbenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 6-trifluoromethylpyridine-3-carbaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 4-methoxybenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 4-tert-butylbenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 4-chloro-3-trifluoromethylbenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 3-chloro-4-methylbenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 3,4-dichlorobenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 3,5-dichlorobenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 3,4-dimethylbenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 3,4-dimethoxybenzaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 1,3-benzodioxan-5-formaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 2,3-dihydro-1H-indole-5-formaldehyde was used as a starting material.
  • the prepared substituted benzyl alcohol was dissolved in 100 mL of DCM, 70 mmol of MnO 2 was added under stirring, and reacted at room temperature for 4 h, filtered, and the filtrate was concentrated by spin-drying and purified by column to obtain 5,6,7,8-tetrahydronaphthalene-2. - Formaldehyde, yield 90%.
  • the subsequent step of preparing the target compound is similar to that of Example 1.
  • the preparation method was similar to that of Example 1, except that 6-methoxy-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 6-bromo-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 5-ben-2-naphthaldehyde was replaced with 5-chloro-2-naphthaldehyde.
  • the 5-chloro-2-naphthaldehyde is obtained by the main method as follows:
  • 5-Bromo-2 naphthoic acid (0.75 g, 3 mmol) was dispersed in 10 mL of methanol, and cooled in an ice bath. 1 mL of concentrated sulfuric acid was slowly added dropwise to the reaction mixture, and the mixture was refluxed for 2 hours, and 20 mL of water was added thereto, followed by extraction with DCM. The organic phase was washed successively with a saturated aqueous sodium hydrogen sulfate solution and brine, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated to give methyl 5-bromo-2-naphthoate.
  • Methyl 5-chloro-2 naphthoate (0.44 g, 2 mmol) was dissolved in 10 mL of anhydrous THF, and then argon gas was applied, and LiAlH 4 (0.1 g, 2.6 mmol) was slowly added thereto in portions under ice bath. After reacting for 10 minutes in an ice bath, it was kept at room temperature for 12 hours, cooled in an ice bath, and 0.1 g of ice water, 0.1 g of a 15% aqueous NaOH solution, and 0.3 g of water were slowly added thereto in this order.
  • Phenol (705 mg, 7.5 mmol), p-fluorobenzaldehyde (625 mg, 5.0 mmol) and K 2 CO 3 (1.38 g, 10.0 mmol) were dispersed in 5 mL DMSO, argon-protected and reacted at 110 ° C overnight. After cooling to room temperature, an appropriate amount of water was added, and the mixture was extracted with ethyl acetate. The organic phase was combined, washed three times with saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness. The subsequent preparation of the final product was the same as in Example 1.
  • the preparation method was similar to that of Example 14, except that [1,1'-biphenyl]-4-carboxylic acid was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 1H-indole-6-formaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 1-methyl-1H-indole-6-formaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 3-quinolinaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 3-isoquinolinecarboxaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 7-quinolinaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 6-isoquinolinecarboxaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that benzothiophene-2-carbaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that benzothiophene-6-formaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that benzofuran-2-carbaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that benzofuran-6-formaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 35 except that triethyl phosphonoacetate was replaced with 2-phosphonopropionic acid triethyl ester.
  • the preparation method was similar to that of Example 35, except that 1-(naphthalen-2-yl)-1-ethanone was replaced with 2-naphthaldehyde, and phosphorus oxyacetate was replaced with 2-phosphonobutyrate triethyl acrylate. Ethyl ester.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-4-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-chlorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-bromobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-trifluoromethylbenzoic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-methylbenzoic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-methoxybenzoic acid.
  • the preparation method was similar to that of Example 1, except that 1-fluoro-2-naphthaldehyde was used as a raw material.
  • the 1-fluoro-2-naphthaldehyde can be prepared as follows:
  • 2-methyl-1-naphthylamine (1.57 g, 10 mmol) was added to a 100 mL eggplant-shaped flask, and fluoroboric acid (15 mL) was added dropwise to the reaction flask, and the mixture was cooled in an ice bath, and 10 mL of NaNO 2 was slowly added dropwise to the reaction solution.
  • the solution (2.76 g, 40 mmol) was reacted for 0.5 h in an ice bath, suction filtered, and the filter cake was dried to give diazonium salt.
  • the obtained diazonium salt was added to 50 mL of toluene, reacted at 90 ° C for 1 h, and refluxed for 2 h.
  • the reaction solution was washed successively with a saturated NaHCO 3 solution and brine, dried over anhydrous sodium sulfate, and evaporated.
  • the obtained concentrate was dissolved in 10 mL of dioxane, 10 mL of water, 20 mmol of CaCO 3 was added , refluxed for 10 h, filtered, ethyl acetate was extracted, the organic phase was combined, dried over anhydrous sodium sulfate, 1-fluoronaphthalen-2-yl)methanol, yield 80%.
  • the preparation method was similar to that of Example 37 except that 1-fluoro-2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 1-fluoro-2-naphthaldehyde was used as a raw material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 1-chloro-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 1-chloro-2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 37 except that 1-chloro-2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 1-bromo-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 37 except that 1-bromo-2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 1-bromo-2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 1-fluoro-6-methoxy-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 6-bromo-1-fluoro-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 1,6-dichloro-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 1,6-dichloro-2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-5-fluorobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 5-chloro-1-fluoro-2-naphthaldehyde was used as a starting material.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-3-thiophenecarboxylic acid.
  • the 2-amino-3-thiophenecarboxylic acid can be obtained by the main method as follows:
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-4-methylthiophene-3-carboxylic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-amino-4,5-dimethylthiophene-3-carboxylic acid.
  • the preparation method of the raw material (E)-2-methyl-3-(naphthalen-2-yl)acrylic acid is similar to the synthesis method of (E)-2-methyl-3-phenylacrylic acid in Example 1, except that the difference lies in 2-naphthaldehyde is used as a starting material.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with o-cyanobenzoic acid.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-aminobenzamide.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 2-aminopyridine.
  • the preparation method was similar to that of Example 1, except that 2-naphthaldehyde was used as a starting material, and anthranilic acid was replaced with 1-amino-2-cyano-1-cyclopentene.
  • DHODH can catalyze the oxidation of its natural substrate DHO (dihydroorotate) to Orotate under certain conditions.
  • DHODH dihydroorotate
  • the two H + and e - of the substrate DHO are first transferred to the coenzyme FMN, and then the reduced FMNH 2 transfers electrons to the free coenzyme Q.
  • the free coenzyme Q eventually delivers electrons to the chromogenic substrate DCIP, which is reduced.
  • DCIP has maximum light absorption at 600 nm, while the reduced DCIP has no light absorption at 600 nm.
  • the degree to which the substrate DHO is oxidized can be judged based on the degree of decrease in absorbance.
  • the degree of oxidation of the substrate DHO per unit time is the initial rate of the enzymatic reaction. After the addition of the inhibitor, the initial rate of the enzymatic reaction is lowered.
  • the 96-well plate was used for the measurement, and the absorbance at 600 nm was read by a BioTek microplate reader. 199 ⁇ L of assay buffer (50 mM HEPES (pH 8.0), 0.15 M KCl, 0.1% Triton X-100, 100 ⁇ M CoQ, 100 ⁇ M DCIP) was added to each well. Add 0.4 ⁇ L of compound, incubate for 5 min at room temperature, then add 1 ⁇ L of substrate DHO (final concentration of 500 ⁇ M) to each well and mix well.
  • assay buffer 50 mM HEPES (pH 8.0), 0.15 M KCl, 0.1% Triton X-100, 100 ⁇ M CoQ, 100 ⁇ M DCIP

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un dérivé d'acrylamide N-substitué, représenté par la formule générale I, en tant qu'inhibiteur de DHODH, ainsi que sa préparation et son utilisation. Le dérivé d'acrylamide N-Substitué a une excellente activité d'inhibition de DHODH, et peut donc être utilisé pour traiter ou prévenir des maladies médiées par DHODH, comprenant, mais sans y être limitées, les maladies auto-immunes, telles que les cancers, la polyarthrite rhumatoïde, le lupus érythémateux, et les rejets de greffes d'organes, et les maladies inflammatoires, telles que la colite et la rhinite.
PCT/CN2019/081066 2018-04-11 2019-04-02 Dérivé d'acrylamide n-substitué en tant qu'inhibiteur de dhodh, sa préparation et son utilisation WO2019196714A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810321850.X 2018-04-11
CN201810321850.XA CN110357789B (zh) 2018-04-11 2018-04-11 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途

Publications (1)

Publication Number Publication Date
WO2019196714A1 true WO2019196714A1 (fr) 2019-10-17

Family

ID=68162813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/081066 WO2019196714A1 (fr) 2018-04-11 2019-04-02 Dérivé d'acrylamide n-substitué en tant qu'inhibiteur de dhodh, sa préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN110357789B (fr)
WO (1) WO2019196714A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023166303A1 (fr) * 2022-03-02 2023-09-07 Nrg Therapeutics Ltd Composés d'acrylamide

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111991380B (zh) * 2020-09-28 2021-06-25 郑州大学第一附属医院 一种中药天然产物的衍生物在抑制食管癌生长和转移方面的应用
CN112876754A (zh) * 2021-01-21 2021-06-01 湖南工业大学 一种生物基抗氧剂改性橡胶及其制备方法
CN113018281B (zh) * 2021-02-23 2023-02-03 中国人民解放军海军军医大学 一种Pellino1天然小分子抑制剂及其应用
CN115010622B (zh) * 2022-06-20 2024-01-09 山东百启生物医药有限公司 一种2-溴-5-氰基苯甲醛的制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50135047A (fr) * 1974-04-16 1975-10-25
US3940422A (en) * 1973-01-18 1976-02-24 Kissei Yakuhin Kogyo Kabushiki Kaisha Aromatic carboxylic amide derivatives
JPS5283429A (en) * 1975-12-31 1977-07-12 Kissei Pharmaceut Co Ltd Preparation of aromatic unsaturated carboxylic acid amide derivatives
JPS5738759A (en) * 1981-01-23 1982-03-03 Kissei Pharmaceut Co Ltd Preparation of novel aromatic carboxylic acid derivative
JPS59122449A (ja) * 1982-12-28 1984-07-14 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS6019754A (ja) * 1983-07-14 1985-01-31 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS6097946A (ja) * 1983-11-01 1985-05-31 Ono Pharmaceut Co Ltd カルボキサミド誘導体
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
CN1273579A (zh) * 1997-08-05 2000-11-15 美国家用产品公司 氨茴酸类似物
CN101094829A (zh) * 2004-12-07 2007-12-26 富山化学工业株式会社 新的氨茴酸衍生物或其盐
CN102164887A (zh) * 2007-12-21 2011-08-24 法博太科制药有限公司 抗纤维化剂的卤代类似物
CN103228275A (zh) * 2010-11-24 2013-07-31 法博太科制药有限公司 治疗与炎症和血管增生相关之眼病的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19935219A1 (de) * 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
TW200616613A (en) * 2004-10-05 2006-06-01 Shionogi & Co Biaryl derivatives
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
JP2019112307A (ja) * 2016-04-28 2019-07-11 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物および他の乾癬治療薬が組み合わせて投与される医薬組成物

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940422A (en) * 1973-01-18 1976-02-24 Kissei Yakuhin Kogyo Kabushiki Kaisha Aromatic carboxylic amide derivatives
JPS50135047A (fr) * 1974-04-16 1975-10-25
JPS5283429A (en) * 1975-12-31 1977-07-12 Kissei Pharmaceut Co Ltd Preparation of aromatic unsaturated carboxylic acid amide derivatives
JPS5738759A (en) * 1981-01-23 1982-03-03 Kissei Pharmaceut Co Ltd Preparation of novel aromatic carboxylic acid derivative
JPS59122449A (ja) * 1982-12-28 1984-07-14 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS6019754A (ja) * 1983-07-14 1985-01-31 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS6097946A (ja) * 1983-11-01 1985-05-31 Ono Pharmaceut Co Ltd カルボキサミド誘導体
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
CN1273579A (zh) * 1997-08-05 2000-11-15 美国家用产品公司 氨茴酸类似物
CN101094829A (zh) * 2004-12-07 2007-12-26 富山化学工业株式会社 新的氨茴酸衍生物或其盐
CN102164887A (zh) * 2007-12-21 2011-08-24 法博太科制药有限公司 抗纤维化剂的卤代类似物
CN103228275A (zh) * 2010-11-24 2013-07-31 法博太科制药有限公司 治疗与炎症和血管增生相关之眼病的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIAO, Y. Y. ET AL.: "Discovery of Diverse Human Dihydroorotate Dehydrogenase Inhibitors as Immunosuppressive Agents by Structure-Based Virtual Screening", J. MED. CHEM., vol. 55, 17 September 2012 (2012-09-17), pages 8341 - 8349, XP055643334 *
KERMANY, E. T. ET AL., SYNTHESIS OF 2-ALKENYL-4H-3, 1 -BF.NZOXAZTN-4-ONF UNDER ACIDIC AND BASIC MEDIA, vol. 4, no. 1, 31 December 2014 (2014-12-31), pages 17 - 21, XP055643343 *
MCCARTHY, D. J. ET AL.: "Use of Structure-Based Drug Design Approaches to Obtain Novel Anthranilic Acid Acyl Carrier Protein Synthase Inhibitors", J. MED. CHEM., vol. 48, 16 November 2005 (2005-11-16), pages 7960 - 7969, XP055643346 *
WILLIAMS, S. J. ET AL.: "3',4'-Bis-difluoromethoxycinnamoylanthranilate (FT061): An orally- active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, 8 October 2013 (2013-10-08), pages 6868 - 6873, XP028788001, DOI: 10.1016/j.bmcl.2013.09.100 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023166303A1 (fr) * 2022-03-02 2023-09-07 Nrg Therapeutics Ltd Composés d'acrylamide

Also Published As

Publication number Publication date
CN110357789B (zh) 2022-09-30
CN110357789A (zh) 2019-10-22

Similar Documents

Publication Publication Date Title
CN110357789B (zh) 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途
JP4482513B2 (ja) Ｎ２−（置換アリールメチル）−３−（置換フェニル）インダゾールおよびこれを含む抗血管形成剤
EP2435407B1 (fr) Dérivés de carboxamide substitués par aryle comme inhibiteurs des canaux calciques ou sodiques
JP4426660B2 (ja) ピラゾール誘導体、その製法および医薬としてのその使用
TWI296625B (en) Novel cyclic amide derivatives
TWI337607B (en) Piperidyl- and piperazinyl-alkylcarbamate derivatives, preparation and therapeutic application thereof
CA2646430A1 (fr) Derives bicycliques de l'acide carboxylique utiles dans le traitement de troubles metaboliques
TW200930369A (en) Bis-(sulfonylamino) derivatives in therapy
TW200901992A (en) Triazolopyridine carboxamide and triazolopyrimidine carboxamide derivatives, their preparation and their application in therapeutics
MXPA01012903A (es) Compuestos de 5-aril-1h-1, 2, 4-triazola como inhibidores de ciclooxigenasa-2 y composiciones farmaceuticas que los contienen.
KR20040030668A (ko) 헤테로아릴설포닐 측쇄를 갖는 안트라닐산 아미드, 이의제조방법, 약제 또는 진단제로서의 이의 용도 및 당해화합물을 함유하는 약제학적 제제
US8299066B2 (en) Compounds having NPY Y5 receptor antagonistic activity
WO2017198178A1 (fr) Dérivé de thiazole et utilisations
JP4492848B2 (ja) ２環性化合物
JP2007015928A (ja) 新規オレフィン誘導体
WO2013075596A1 (fr) Dérivé de cétone hétérocyclique dihydrogénée pentabasique comme inhibiteur de dhodh et applications associées
WO2011145669A1 (fr) Dérivé d'amide
TW201100073A (en) Bis-(sulfonylamino) derivatives in therapy 735
TW201000458A (en) Isoquinolinone derivatives as NK3 antagonists
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
JP2002020386A (ja) ピラゾロピリジン誘導体
TW201035050A (en) Bis aromatic compounds for use as LTC4 synthase inhibitors
JP5072965B2 (ja) 高選択性および経口有効性ｃｏｘ−２インヒビターである３−置換−１，５−ジアリール−２−アルキルピロール
EP3330263B1 (fr) Dérivés de phénylurée en tant qu'inhibiteurs de dehydrogenase 2 d'isocitrate pour le traitement du cancer
AU2015247575C1 (en) Polycyclic hERG activators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19785800

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19785800

Country of ref document: EP

Kind code of ref document: A1